Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05069259
Other study ID # A3921395
Secondary ID KIC-START
Status Recruiting
Phase
First received
Last updated
Start date March 28, 2022
Est. completion date October 21, 2024

Study information

Verified date April 2024
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email ClinicalTrials.gov_Inquiries@pfizer.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is expected to contribute to the body of real-world data of tofacitinib's safety and efficacy profile in ulcerative colitis. Conventional clinical outcomes will give a better understanding of response and remission rates in a representative, post-marketing population. Regular patient questionnaires and measurement of a biomarker of gut inflammation will provide detail on how patients experience induction treatment and contextualise the efficacy data.


Description:

This is a low-interventional study in which the intervention under study is home fecal calprotectin testing which falls outside of normal standard of care in ulcerative colitis. Tofacitinib is prescribed and administered as per the Swiss prescribing information. Accordingly, this study is registered on ClinicalTrials.gov as an interventional study. Under Swiss law, this study is considered and approved as a non-interventional study (Category A, Human Research Ordinance, Swiss Confederation).


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 21, 2024
Est. primary completion date October 21, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female participants 18 years of age or older at screening visit - Participants with confirmed diagnosis of UC and who are prescribed tofacitinib (Xeljanz®) for moderately to severely active UC as per the Swiss label - Participants who are willing and able to comply with all scheduled visits, treatment plan, study interventions, and other study procedures - Capable of giving personally signed informed consent Exclusion Criteria: - Presence of clinical findings suggestive of Crohn's disease - Any previous exposure to tofacitinib including participation in the tofacitinib clinical program - Co-medication with any other advanced therapies for UC (biologics*, azathioprine, mercaptopurine and methotrexate) or any other JAK inhibitor - Any identified contra-indications for use of tofacitinib as per the Swiss label - Not owning a handheld digital device compatible with the Sidekick Health App, not willing to have it installed on this device or not capable of using the App - Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Stool sample collection
collection for measuring calprotectin levels

Locations

Country Name City State
Switzerland Clarunis, Universitätsspital Basel
Switzerland Inselspital Bern Bern Bern (de)
Switzerland Verein IBD Study Group Bern
Switzerland Centre Fribourgeois de Gastroenterologie Fribourg
Switzerland Kantonsspital Baselland Liestal
Switzerland Kantonsspital St, Gallen St. Gallen Sankt Gallen
Switzerland Zentrum für Gastroenterologie und Hepatologie Zuerich
Switzerland University Hospital Zurich Zurich
Switzerland University Hospital Zurich Zurich

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants achieving clinical response Clinical response is defined as a reduction in the Partial Mayo Score from baseline of =2 points or achieving clinical remission.
Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Week 8
Secondary Proportion of participants achieving clinical remission Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1. Week 8, Week 16
Secondary Proportion of participants achieving clinical response Clinical response is defined as a reduction in the Partial Mayo Score from baseline of =2 points or achieving clinical remission.
Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Week 16
Secondary Proportion of participants achieving Inflammatory Bowel Disease Questionnaire remission Inflammatory Bowel Disease Questionnaire remission is defined as an Inflammatory Bowel Disease Questionnaire score = 170.
The Inflammatory Bowel Disease Questionnaire is a 32-item questionnaire grouped into four dimensions: bowel function, emotional status, systemic symptoms and social function. The total Inflammatory Bowel Disease Questionnaire score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Week 8, Week 16
Secondary Proportion of participants achieving Inflammatory Bowel Disease Questionnaire response Inflammatory Bowel Disease Questionnaire response is defined as an Inflammatory Bowel Disease Questionnaire score =16 points higher than Inflammatory Bowel Disease Questionnaire baseline score. Week 8, Week 16
Secondary Proportion of participants achieving biochemical remission Biochemical remission is defined as a fecal calprotectin concentration =250 mg/g.
Fecal calprotectin is a small anti-microbial protein detected in stool that constitutes approximately 60% of neutrophil cytoplasm. As migration of neutrophils into the intestinal mucosa is a hallmark of active intestinal inflammation, fecal calprotectin serves as a noninvasive biomarker for intestinal inflammation.
Week 8, Week 16
Secondary Change from baseline in fecal calprotectin concentrations over time. Median change from baseline in fecal calprotectin concentrations over time. Fecal calprotectin concentration is a continuous outcome. Baseline to Week 16
Secondary Fecal calprotectin concentrations over time stratified by Week 8 clinical remission status Median fecal calprotectin concentrations over time stratified by participants' Week 8 clinical remission status.
Clinical remission status is either achieved or not achieved. Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Baseline to Week 16
Secondary Fecal calprotectin concentrations over time stratified by Week 16 clinical remission status Median fecal calprotectin concentrations over time stratified by participants' Week 16 clinical remission status.
Clinical remission status is either achieved or not achieved. Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Baseline to Week 16
Secondary Fecal calprotectin concentrations over time stratified by Week 8 clinical response status. Median fecal calprotectin concentrations over time stratified by participants' Week 8 clinical response status.
Clinical response status is either achieved or not achieved. Clinical response is defined as a reduction in the Partial Mayo Score from baseline of =2 points or achieving clinical remission.
Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Baseline to Week 16
Secondary Fecal calprotectin concentrations over time stratified by Week 16 clinical response status Median fecal calprotectin concentrations over time stratified by participants' Week 16 clinical response status.
Clinical response status is either achieved or not achieved. Clinical response is defined as a reduction in the Partial Mayo Score from baseline of =2 points or achieving clinical remission.
Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Baseline to Week 16
Secondary Fecal calprotectin concentrations stratified by Week 8 clinical response status Median fecal calprotectin concentrations at Week 8 stratified by participants' Week 8 clinical response status. Clinical response status is either achieved or not achieved. Clinical response is defined as a reduction in the Partial Mayo Score from baseline of =2 points or achieving clinical remission.
Clinical remission is defined as Partial Mayo Score of = 2 with no subscore >1.
Week 8
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and Inflammatory Bowel Disease Questionnaire score Correlations are assessed by the Spearman correlation coefficient. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and fecal calprotectin concentration Correlations are assessed by the Spearman correlation coefficient. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of patient reported outcomes and fecal calprotectin concentration Correlations are assessed by the Spearman correlation coefficient. There are eight individual patient reported outcomes: stool frequency, rectal bleeding, urgency of defecation, abdominal pain, quality of sleep, daily fatigue, weekly fatigue and quality of life. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of patient reported outcomes and Inflammatory Bowel Disease Questionnaire score Correlations are assessed by the Spearman correlation coefficient. There are eight individual patient reported outcomes: stool frequency, rectal bleeding, urgency of defecation, abdominal pain, quality of sleep, daily fatigue, weekly fatigue and quality of life. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Inflammatory Bowel Disease Questionnaire score and fecal calprotectin concentration. Correlations are assessed by the Spearman correlation coefficient. Baseline to Week 16
Secondary Change from baseline in stool frequency patient-reported outcome over time. Median change from baseline in each stool frequency patient-reported outcome over time.
The stool frequency patient-reported outcome is assessed with one question about the number of stools on a given day. The Mayo Score stool frequency subscore is used for scoring. Scores range from 0 to 3 and higher scores indicate more severe disease activity. Each participant serves as his or her own control to establish the degree of abnormality of stool frequency.
Baseline to Week 16
Secondary Change from baseline in rectal bleeding patient-reported outcome over time. Median change from baseline in each rectal bleeding patient-reported outcome over time.
The rectal bleeding patient-reported outcome is assessed with one question about most severe rectal bleeding on a given day. The Mayo Score rectal bleeding subscore is used for scoring. Scores range from 0 to 3 and higher scores indicate more severe disease activity. Each participant serves as his or her own control to establish the degree of rectal bleeding.
Baseline to Week 16
Secondary Change from baseline in urgency of defecation patient-reported outcome over time. Median change from baseline urgency of defecation patient-reported outcome over time.
The Urgency of defecation patient-reported outcome is assessed with the Urgency Numeric Rating Scale. Scoring is done on a 11-point numeric rating scale. Participant can input a score from 0 to 10. Higher scores indicate more severe urgency.
Baseline to Week 16
Secondary Change from baseline in abdominal pain patient-reported outcome over time. Median change from baseline in abdominal pain patient-reported outcome over time.
The abdominal pain patient-reported outcome is assessed with the Pain Numeric Rating Scale. Scoring is done on a 10-point horizontal numeric rating scale. Participant can input a score from 1 to 10. Higher scores indicate more severe pain.
Baseline to Week 16
Secondary Change from baseline in quality of sleep patient-reported outcome over time. Median change from baseline in quality of sleep patient-reported outcome over time.
The quality of sleep patient-reported outcome is assessed with a question from the Sleep Quality visual analogue scale survey. Scoring is done on a 11-point numeric rating scale. Participant can input a score from 0 to 10. Higher scores indicate better quality of sleep.
Baseline to Week 16
Secondary Change from baseline in daily fatigue patient-reported outcome over time. Median change from baseline in daily fatigue patient-reported outcome over time.
The daily fatigue patient-reported outcome is assessed with the Fatigue numeric rating scale. Scoring is done on a 11-point numeric rating scale. Participant can input a score from 0 to 10. Higher scores indicate more severe fatigue.
Baseline to Week 16
Secondary Change from baseline in weekly fatigue patient-reported outcome over time. Median change from baseline in each weekly fatigue patient-reported outcome over time.
The weekly fatigue patient-reported outcome is assessed with 13 questions from the ("Additional concerns" section) FACIT-F (Version 4). Scoring is done on a Responses are recorded on a 5-point Likert scale. Scores range from 0 to 52, with higher scores representing greater fatigue.
Baseline to Week 16
Secondary Change from baseline in Inflammatory Bowel Disease Questionnaire score over time. The Inflammatory Bowel Disease Questionnaire is a 32-item questionnaire on quality of life. The total Inflammatory Bowel Disease Questionnaire score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and stool frequency patient-reported outco Correlations are assessed by the Spearman correlation coefficient. The stool frequency patient-reported outcome is assessed with one question about the number of stools on a given day. The Mayo Score stool frequency subscore is used for scoring. Scores range from 0 to 3 and higher scores indicate more severe disease activity. Each participant serves as his or her own control to establish the degree of abnormality of stool frequency. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and rectal bleeding patient-reported outcome. Correlations are assessed by the Spearman correlation coefficient. The rectal bleeding patient-reported outcome is assessed with one question about most severe rectal bleeding on a given day. The Mayo Score rectal bleeding subscore is used for scoring. Scores range from 0 to 3 and higher scores indicate more severe disease activity. Each participant serves as his or her own control to establish the degree of rectal bleeding. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and urgency of defecation patient-reported outcome. Correlations are assessed by the Spearman correlation coefficient. The Urgency of defecation patient-reported outcome is assessed with the Urgency Numeric Rating Scale. Scoring is done on a 11-point numeric rating scale. Participant can input a score from 0 to 10. Higher scores indicate more severe urgency. Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and abdominal pain patient-reported outcome. Correlations are assessed by the Spearman correlation coefficient. The abdominal pain patient-reported outcome is assessed with the Pain Numeric Rating Scale. Scoring is done on a 10-point horizontal numeric rating scale. Participant can input a score from 1 to 10. Higher scores indicate more severe pain.
Scoring is done on a 10-point horizontal numeric rating scale. Participant can input a score from 1 to 10. Higher scores indicate more severe pain.
Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and quality of sleep patient-reported outcome. Correlations are assessed by the Spearman correlation coefficient. The quality of sleep patient-reported outcome is assessed with a question from the Sleep Quality visual analogue scale survey.
Scoring is done on a 11-point numeric rating scale. Participant can input a score from 0 to 10. Higher scores indicate better quality of sleep.
Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and daily fatigue patient-reported outcome. Correlations are assessed by the Spearman correlation coefficient. The daily fatigue patient-reported outcome is assessed with the Fatigue numeric rating scale.
Scoring is done on a 11-point numeric rating scale. Participant can input a score from 0 to 10. Higher scores indicate more severe fatigue.
Baseline to Week 16
Secondary Correlations between changes in amplitude and timing of Partial Mayo Score and weekly fatigue patient-reported outcome. Correlations are assessed by the Spearman correlation coefficient. The weekly fatigue patient-reported outcome is assessed with 13 questions from the ("Additional concerns" section) FACIT-F (Version 4). Scoring is done on a Responses are recorded on a 5-point Likert scale. Scores range from 0 to 52, with higher scores representing greater fatigue. Baseline to Week 16
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2